Predictors of Treatment Failure in Children With HIV Starting First-line Antiretroviral Therapy in the ODYSSEY Trial

Clinical Infectious Diseases 2026 Open access

Read full text
Authors: James Wyncoll, Rujirek Kamolrattana, Moherndran Archary, Hilda A. Mujuru, Adeodata R Kekitiinwa, Avy Violari, Sathaporn Na-Rajsima, Abbas Lugemwa, Ebrahim Variava, M. F. Cotton, Cissy M Kityo, C Königs
+13 more Ngundu Osee Behuhuma, Steve Welch, Yacine Saïdi, Laura Marques, Grace M Ahimbisibwe, Lily Houlden, Carlo Giaquinto, Pablo Rojo, D. M. F. Gibb, Thanyawee Puthanakit, Anna Turkova, Ellen White, D. J. Ford
DOI: 10.1093/cid/ciag232
Cited by: 1
References: 29

Abstract

BACKGROUND: Data on predictors of treatment failure in children starting antiretroviral therapy (ART) are limited, particularly on dolutegravir-based regimens (DTG). METHODS: ODYSSEY demonstrated superior efficacy of DTG versus standard-of-care (SOC). We assessed predictors at ART initiation of treatment failure by 96 weeks. RESULTS: Three hundred and eighty-one children started first-line ART (82% African). At ART-initiation, median age was 10.5 years (IQR: 6.5, 14.0, 67 < 3 years), CD4% 20% (IQR: 12, 28), BMI-for-age Z-score -.58 (IQR:-1.48, +.25). One hundred and eighty-nine children started DTG, 192 started SOC (91% ≥3 years started efavirenz; 79%

Fields of Study & Subjects

HIV-related health complications and treatments HIV/AIDS drug development and treatment HIV/AIDS Research and Interventions

Publication details

Journal / source
Clinical Infectious Diseases
Publisher
Oxford University Press (OUP)
Volume
83
Issue
2
Pages
e320–e328
Publication date
9 April 2026
Language
EN